WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 329453
CAS#: 82956-11-4 (mesylate)
Description: Nafamostat, also known as FUT-175, is a serine protease inhibitor and an anticoagulant. Nafamostat promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway. Nafamostat Attenuates Ischemia-Reperfusion-Induced Renal Injury. Nafamostat Attenuates Ischemia-Reperfusion-Induced Renal Injury. Nafamostat protects against acute cerebral ischemia via blood-brain barrier protection. Nafamostat Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production. Researchers have identified the drug as a potential therapy for COVID-19,[ with clinical trials in Japan possibly set to begin in March 2020.
MedKoo Cat#: 329453
Name: Nafamostat mesylate
CAS#: 82956-11-4 (mesylate)
Chemical Formula: C21H25N5O8S2
Molecular Weight: 539.58
Elemental Analysis: C, 46.75; H, 4.67; N, 12.98; O, 23.72; S, 11.88
Related CAS #: 81525-10-2 (free base) 82956-11-4 (mesylate) 80251-32-7 (HCl)
Synonym: Nafamostat mesylate; nafamostat mesilate; FUT-175; FUT 175; FUT175.
IUPAC/Chemical Name: 6-Amidino-2-naphthyl 4-guanidinobenzoate dimethanesulfonate
InChi Key: SRXKIZXIRHMPFW-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H17N5O2.2CH4O3S/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23;2*1-5(2,3)4/h1-10H,(H3,20,21)(H4,22,23,24);2*1H3,(H,2,3,4)
SMILES Code: CS(=O)(O)=O.CS(=O)(O)=O.O=C(OC1=CC=C2C=C(C(N)=N)C=CC2=C1)C3=CC=C(NC(N)=N)C=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
|Biological target:||Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant that supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis.|
|In vitro activity:||To determine whether nafamostat has neuroprotective effects, its effects on NMDA-induced neuronal cell death were first examined in cultured primary rat cortical neurons. Figure 1 shows the concentration–response curves for the effects of nafamostat on NMDAinduced neuronal cell death in comparison with those of MK-801, an authentic NMDA receptor antagonist used as the positive control. In the absence of either nafamostat or MK-801, the application of 25 µM NMDA to the culture medium resulted in 80% reduction in the cell viability, which reached statistical significance. Nafamostat demonstrated a potent and concentration-dependent neuroprotective effect against NMDA-induced neuronal cell death. This effect was statistically significant in the range from 2.5 to 10 µM and reached the peak at 5 µM. As expected, 10 µM MK-801 also provided statistically significant and complete protection against NMDA-induced neuronal cell death. Thus, nafamostat may have an in vitro neuroprotective effect equivalent to that of MK801, which has been assessed clinically. Reference: Sci Rep. 2019; 9: 20409. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938488/|
|In vivo activity:||This study tested the hypothesis that nafamostat mesilate, a serine protease inhibitor, may ameliorate ischemia-induced neuronal damage through thrombin inhibition after ischemic stroke. Focal ischemia was induced in adult Sprague-Dawley rats by occlusion of the middle cerebral artery for 2 hours followed by 22 hours of reperfusion. A high expression level and activity of thrombin are associated with brain damage after ischemic stroke9,12,17,18. Owing to NM's activity as a serine protease inhibitor, we determined whether NM treatment could inhibit thrombin expression and activity in the striatum lesion at 24 hours after MCAO. The results from Western blotting showed that NM treatment dose-dependently decreased the expression of thrombin from an ischemic striatum lesion (Fig. 3A). We also found that brain thrombin activity in the vehicle group at 24 hours after MCAO was significantly higher than that in the sham group; however, NM treatment (0.1 mg/kg and 1 mg/kg) significantly reduced brain thrombin activity at 24 hours after MCAO (Fig. 3B and C). These results show that NM treatment can decrease thrombin expression and activity in the brains of rats after MCAO. hese results suggest that nafamostat mesilate may have a potential therapeutic role for neuroprotection against focal cerebral ischemia through thrombin inhibition. Reference: Sci Rep. 2014 Jul 2;4:5531. https://pubmed.ncbi.nlm.nih.gov/24985053/|
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|Soluble in DMSO||10.0||18.5|
The following data is based on the product molecular weight 539.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
|Formulation protocol:||1. Inman RD, Chiu B. Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis. Arthritis Res Ther. 2012 Jun 20;14(3):R150. doi: 10.1186/ar3886. PMID: 22716645; PMCID: PMC3446536. 2. Fuwa M, Kageyama M, Ohashi K, Sasaoka M, Sato R, Tanaka M, Tashiro K. Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model. Sci Rep. 2019 Dec 31;9(1):20409. doi: 10.1038/s41598-019-56905-x. PMID: 31892740; PMCID: PMC6938488. 3. Chen T, Wang J, Li C, Zhang W, Zhang L, An L, Pang T, Shi X, Liao H. Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. Sci Rep. 2014 Jul 2;4:5531. doi: 10.1038/srep05531. PMID: 24985053; PMCID: PMC4078306.|
|In vitro protocol:||1. Inman RD, Chiu B. Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis. Arthritis Res Ther. 2012 Jun 20;14(3):R150. doi: 10.1186/ar3886. PMID: 22716645; PMCID: PMC3446536. 2. Fuwa M, Kageyama M, Ohashi K, Sasaoka M, Sato R, Tanaka M, Tashiro K. Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model. Sci Rep. 2019 Dec 31;9(1):20409. doi: 10.1038/s41598-019-56905-x. PMID: 31892740; PMCID: PMC6938488.|
|In vivo protocol:||1. Fuwa M, Kageyama M, Ohashi K, Sasaoka M, Sato R, Tanaka M, Tashiro K. Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model. Sci Rep. 2019 Dec 31;9(1):20409. doi: 10.1038/s41598-019-56905-x. PMID: 31892740; PMCID: PMC6938488. 2. Chen T, Wang J, Li C, Zhang W, Zhang L, An L, Pang T, Shi X, Liao H. Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. Sci Rep. 2014 Jul 2;4:5531. doi: 10.1038/srep05531. PMID: 24985053; PMCID: PMC4078306.|
1: Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, Wei J, Yang X, Shen Q, Gong Z, Yan Y. The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications. Front Oncol. 2019 Sep 3;9:852. doi: 10.3389/fonc.2019.00852. PMID: 31552177; PMCID: PMC6733886.
2: Komi DEA, Redegeld FA. Role of Mast Cells in Shaping the Tumor Microenvironment. Clin Rev Allergy Immunol. 2019 Jun 29. doi: 10.1007/s12016-019-08753-w. Epub ahead of print. PMID: 31256327.
3: Doi K, Nishida O, Shigematsu T, Sadahiro T, Itami N, Iseki K, Yuzawa Y, Okada H, Koya D, Kiyomoto H, Shibagaki Y, Matsuda K, Kato A, Hayashi T, Ogawa T, Tsukamoto T, Noiri E, Negi S, Kamei K, Kitayama H, Kashihara N, Moriyama T, Terada Y; Japanese Clinical Practice Guideline for Acute Kidney Injury 2016 Committee. The Japanese clinical practice guideline for acute kidney injury 2016. Clin Exp Nephrol. 2018 Oct;22(5):985-1045. doi: 10.1007/s10157-018-1600-4. PMID: 30039479; PMCID: PMC6154171.
4: Ghali MGZ, Srinivasan VM, Johnson J, Kan P, Britz G. Therapeutically Targeting Platelet-Derived Growth Factor-Mediated Signaling Underlying the Pathogenesis of Subarachnoid Hemorrhage-Related Vasospasm. J Stroke Cerebrovasc Dis. 2018 Sep;27(9):2289-2295. doi: 10.1016/j.jstrokecerebrovasdis.2018.02.017. Epub 2018 Jul 20. PMID: 30037648.
5: Sadahiro T, Yuzawa H, Kimura T, Oguchi M, Morito T, Mizushima S, Hirose Y. Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study. Contrib Nephrol. 2018;196:209-214. doi: 10.1159/000485724. Epub 2018 Jul 24. PMID: 30041229.
6: Yahata M, Sakamoto Y. [Anti DIC therapy]. Nihon Rinsho. 2016 Feb;74(2):257-61. Japanese. PMID: 26915249.
7: Leporini C, Ammendola M, Marech I, Sammarco G, Sacco R, Gadaleta CD, Oakley C, Russo E, De Sarro G, Ranieri G. Targeting mast cells in gastric cancer with special reference to bone metastases. World J Gastroenterol. 2015 Oct 7;21(37):10493-501. doi: 10.3748/wjg.v21.i37.10493. PMID: 26457010; PMCID: PMC4588072.
8: Uwagawa T, Yanaga K. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surg Today. 2015 Dec;45(12):1481-8. doi: 10.1007/s00595-015-1129-z. Epub 2015 Feb 12. PMID: 25673034.
9: Kubiliun NM, Adams MA, Akshintala VS, Conte ML, Cote GA, Cotton PB, Dumonceau JM, Elta GH, Fogel EL, Freeman ML, Lehman GA, Naveed M, Romagnuolo J, Scheiman JM, Sherman S, Singh VK, Elmunzer BJ; United States Cooperative for Outcomes Research in Endoscopy (USCORE). Evaluation of Pharmacologic Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Systematic Review. Clin Gastroenterol Hepatol. 2015 Jul;13(7):1231-9; quiz e70-1. doi: 10.1016/j.cgh.2014.11.038. Epub 2015 Jan 9. PMID: 25579870.
10: Hanafusa N. Application of Continuous Renal Replacement Therapy: What Should We Consider Based on Existing Evidence? Blood Purif. 2015;40(4):312-9. doi: 10.1159/000441579. Epub 2015 Nov 17. PMID: 26657106.
11: Ribatti D, Ranieri G. Tryptase, a novel angiogenic factor stored in mast cell granules. Exp Cell Res. 2015 Mar 15;332(2):157-62. doi: 10.1016/j.yexcr.2014.11.014. Epub 2014 Dec 3. PMID: 25478999.
12: Marech I, Ammendola M, Gadaleta C, Zizzo N, Oakley C, Gadaleta CD, Ranieri G. Possible biological and translational significance of mast cells density in colorectal cancer. World J Gastroenterol. 2014 Jul 21;20(27):8910-20. doi: 10.3748/wjg.v20.i27.8910. PMID: 25083063; PMCID: PMC4112891.
13: Al-Horani RA, Desai UR. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders. Med Res Rev. 2014 Nov;34(6):1168-216. doi: 10.1002/med.21315. Epub 2014 Mar 21. PMID: 24659483.
14: Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamillo G, Sacco R, Sammarco G, De Sarro G, Russo E, Ranieri G. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int. 2014;2014:154702. doi: 10.1155/2014/154702. Epub 2014 Sep 11. PMID: 25295247; PMCID: PMC4177740.
15: Wada H, Matsumoto T, Yamashita Y. [Recent therapeutic strategy for disseminated intravascular coagulation]. Rinsho Ketsueki. 2014 Jan;55(1):75-82. Japanese. PMID: 24492040.
16: Tauchi R, Imagama S, Ito Z, Ando K, Hirano K, Ukai J, Kobayashi K, Shinjo R, Muramoto A, Nakashima H, Matsumoto T, Ishiguro N. Acute pancreatitis after spine surgery: a case report and review of literature. Eur J Orthop Surg Traumatol. 2014 Jul;24 Suppl 1:S305-9. doi: 10.1007/s00590-013-1390-z. Epub 2013 Dec 8. PMID: 24318308.
17: Akshintala VS, Hutfless SM, Colantuoni E, Kim KJ, Khashab MA, Li T, Elmunzer BJ, Puhan MA, Sinha A, Kamal A, Lennon AM, Okolo PI, Palakurthy MK, Kalloo AN, Singh VK. Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis. Aliment Pharmacol Ther. 2013 Dec;38(11-12):1325-37. doi: 10.1111/apt.12534. Epub 2013 Oct 20. PMID: 24138390.
18: Dhand A, Aminoff MJ. The neurology of itch. Brain. 2014 Feb;137(Pt 2):313-22. doi: 10.1093/brain/awt158. Epub 2013 Jun 22. PMID: 23794605.
19: Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013 Dec 15;56(3):232-9. doi: 10.1016/j.molimm.2013.05.221. Epub 2013 Jun 17. Erratum in: Mol Immunol. 2014 Aug;60(2):115. PMID: 23787367.
20: Yuhara H, Ogawa M, Kawaguchi Y, Igarashi M, Shimosegawa T, Mine T. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis. J Gastroenterol. 2014 Mar;49(3):388-99. doi: 10.1007/s00535-013-0834-x. Epub 2013 May 30. PMID: 23720090.
81525-10-2 (Nafamostat free base
82956-11-4 (Nafamostat mesylate)